You are here: Industry Insights > LYT-100

News List

PureTech Health reports increase in 2020 revenue pharmaceutical-technology
April 16, 2021
PureTech Health has reported an increase in revenue to $11.77m last year from $9.81m in 2019.
PureTech launches phase II ‘long COVID’ drug trial pharmatimes
December 08, 2020
PureTech has initiated a phase II trial of its investigational drug candidate LYT-100 in long COVID characterised by respiratory complications and related sequelae.
PureTech advances experimental COVID-19 drug into global trials pharmatimes
May 29, 2020
UK clinical-stage biotherapeutics group PureTech has unveiled plans to advance its wholly-owned clinical-stage product candidate LYT-100 (deupirfenidone) as a potential treatment for serious respiratory complications ...
First patient dosed in potential lymphoedema treatment trial pharmatimes
March 06, 2020
PureTech has announced that the first participant has been dosed in a clinical study of LYT-100, the company’s product candidate for the potential treatment of lymphoedema and other fibrotic conditions.